Liquidia enters 5-year supply deal with Plastiape for YUTREPIA inhalers

Liquidia Corp

Supply Agreement with Plastiape SpA for dry powder inhalers used for YUTREPIA (investigational treprostinil).
Initial term of 5 years; no minimum purchase commitment; Company provides non-binding 12-month forecast annually.
Customary termination provisions: material breach, insolvency, price disagreement; additional rights for change of control or repeated delivery failures.
Agreement effective June 7, 2023; will be filed with next 10-Q.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp entered into Supply Agreement with Plastiape SpA (effective 2023-06-07).

Action: entry
Agreement: supply
Counterparty: Plastiape SpA
Effective: 2023-06-07

Exact text from the filing

On June 7, 2023, Liquidia Corporation, a Delaware corporation through Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Liquidia Corporation, entered into a Supply Agreement (the “Agreement”) with Plastiape SpA, a company organized and existing under the laws of Italy (“Plastiape”).

View on SEC.gov

Browse all material agreements →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-069414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.